Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MrMugsyon Jan 10, 2021 3:50pm
356 Views
Post# 32263855

7:00 AM is good ...

7:00 AM is good ...Thanks everyone ... good discussion ... and we do have to keep our expectations in check.  There's a lot of loose ends that need to be tied up and I'm not sure when that comes.  Hoping it's soon.

Maybe we get that shareholder update by 6:30 AM tomorrow ????
The sooner the better for me - waiting long enough.

If Dan ever needed an update to shine - after forging forward with TSX listing and a reverse split ... this is the time !!!

I wouldn't want institutional investors to sit on a flat stock giving them time to make purchases at a bargain-basement price.

I'd want to get the party started quickly by filling in all the blanks ... giving everyone updates on the academic studies, show how it relates to the patent program - sell us on the value being created as we head into P3 for OTENA, human trials for 352 and parallel paths for Aspirin.

Really make it clear what we have here and how it relates to a future of gaseous mediators for a proud owner of ATE shares.  That's what we need now.  That's what would move the share price.

That's what I have been hoping J.P.Morgan would represent to the company, to use and to future shareholders.  Let's see if Dan's got a rocket strapped to his back ... or ... if he's holding a sparkler. 

Put the sparkler away Dan - hahaha !
<< Previous
Bullboard Posts
Next >>